SeqWright to Use 454, NimbleGen Tools in Eli Lilly Collaboration | GenomeWeb

NEW YORK (GenomeWeb News) – Genomic services company SeqWright will use technologies from Roche subsidiaries 454 Life Sciences and NimbleGen to help drug developer Eli Lilly to identify genetic variants associated with psychiatric diseases, Roche said today.

Under the collaboration, SeqWright will use NimbleGen Sequence Capture technology to enrich around 40 megabases of the human genome, which will then be sequenced using 454 Life Sciences Genome Sequencer FLX System.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.